Description

Fazlodex Solution for Injections Syringe 250 mg/5 ml. 5 ml №2

Ingredients:

Fazlodex contains the active ingredient fulvestrant, a selective estrogen receptor degrader (SERD) that works by blocking the estrogen receptors in the body.

Dosage:

The recommended dose of Fazlodex is 500 mg administered intramuscularly into the buttocks, divided into two 5 ml injections. The injections should be given slowly to minimize injection site reactions.

Indications:

Fazlodex is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Contraindications:

Do not use Fazlodex if you are allergic to fulvestrant or any other ingredients in the formulation. It is not recommended for use in premenopausal women.

Directions:

Follow the instructions provided by your healthcare provider for the proper administration of Fazlodex. It is important to rotate injection sites and monitor for any signs of injection site reactions.

Scientific Evidence:

Fazlodex has been extensively studied in clinical trials for its efficacy in treating hormone receptor-positive metastatic breast cancer. Research published in the Journal of Clinical Oncology has shown that fulvestrant significantly improves progression-free survival compared to anastrozole in postmenopausal women with advanced breast cancer.

Additional Information:

In addition to its therapeutic benefits, Fazlodex has a favorable safety profile with manageable side effects. It is important to discuss any existing medical conditions or medications with your healthcare provider before starting treatment with Fazlodex.

Pharmacological Effects: Fulvestrant works by binding to the estrogen receptors in breast cancer cells, leading to their degradation and inhibiting the growth of estrogen-dependent tumors. This mechanism of action differentiates fulvestrant from other endocrine therapies, making it a valuable option in the management of hormone receptor-positive breast cancer.

Clinical Trials: Clinical trials have demonstrated the efficacy of Fazlodex in improving outcomes for women with advanced breast cancer. A study published in Breast Cancer Research and Treatment showed that fulvestrant was well-tolerated and effective in postmenopausal women with hormone receptor-positive metastatic breast cancer who had progressed on prior endocrine therapy.